SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Glaxosmithkline Pharmaceuticals Ltd

BSE: 500660 NSE: GLAXO ISIN: INE159A01016
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Glaxosmithkline Pharmaceuticals Ltd belong to?
Glaxosmithkline Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Glaxosmithkline Pharmaceuticals Ltd a good quality company?
Glaxosmithkline Pharmaceuticals Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Glaxosmithkline Pharmaceuticals Ltd undervalued or overvalued?
Glaxosmithkline Pharmaceuticals Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Glaxosmithkline Pharmaceuticals Ltd a good buy now?
Glaxosmithkline Pharmaceuticals Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd revenue growth is 8.6% for FY-2025 , which is above its 5 year CAGR of 3.1% , indicating faster growth.
Q.2 Gross Profit margin of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 32.1% for FY-2025 , which is above its 5 year median of 25.3% , indicating increasing margins.
Q.3 Operating Profit Margin of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 31.5% for FY-2025 , which is above its 5 year median of 25.04% indicating increasing margins.
Q.4 Net Profit Margin of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Net Profit Margin is 24.74% for FY-2025 , is above with its 5 year median of 17.08%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 32.1 25.3
Operating Profit Margin 31.5 25.04
Net Profit Margin 24.74 17.08
Q.5 Return on Asset of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Return on Asset is 25.15%, which is above its 5 year historical median of 15.76%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Return on equity is 49.43% for FY-2025 , which is above its historical median of 27.58%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Return on capital employed is 67.64% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation.
Q.8 Cash conversion cycle of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Cash conversion cycle is -37 days, below its historical median of -12 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.12 1.04
ROE 49.43 27.58
ROCE 67.64 38.06
Cash Conversion Cycle -37 days -12 days
Q.9 Debt to Equity ratio of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.13 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Glaxosmithkline Pharmaceuticals Ltd?
Promoters hold 75.00% of the Glaxosmithkline Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Glaxosmithkline Pharmaceuticals Ltd vs industry peers?
Glaxosmithkline Pharmaceuticals Ltd revenue CAGR is 3.06% , compared to the industry median CAGR of 8.87% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 3,749.2 8,127.2
Gross Profit 1,203.4 1,337.7
Operating Profit 1,177 1,810
Net Profit 928 970
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.12 0.8
ROE 49.43 18.61
ROCE 67.64 17.96
Cash Conversion Cycle (days) -36.77 76

Valuation & price assessment

Q.1 Stock return of Glaxosmithkline Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 2.8% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 2.8% 10.9% 25.3% -15.5%
Q.3 Valuation ratios of Glaxosmithkline Pharmaceuticals Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 40.14 0.00 40.28
Price to Book 20.46 13.91 2.77
Price to Sales 10.78 8.71 2.65
EV to EBITDA 27.91 36.20 15.67

Check more companies

1. Lupin
2. Dr. Reddys Lab
3. Zydus Lifesciences
4. Mankind Pharma
5. Aurobindo Pharma
6. Alkem Laboratories
7. Glenmark Pharma
8. Laurus Labs
9. Biocon
10. Abbott India
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×